Positive early results from a drug tested on people with advanced bladder cancer continued in a larger data set reviewed recently, the drug's maker, AstraZeneca, has reported.
“The durable responses
observed in this larger data set from Study 1108 confirm the promising
efficacy we’ve already seen for durvalumab in patients with advanced
bladder cancer," David Berman, senior vice president and Head of
Oncology Innovative Medicines at MedImmune, said.
AstraZeneca and its global biologics research and development arm, MedImmune, announced the updated efficacy and safety data for durvalumab in patients with locally advanced or metastatic urothelial cancer (UC) during the 2017 ASCO Genitourinary Cancers Symposium.
The combination of durvalumab and tremelimumab is also being studied in non-small cell lung cancer, head and neck squamous cell carcinoma, gastric cancer, pancreatic cancer, hepatocellular carcinoma and haematological malignancies.
“The clinical efficacy of durvalumab in patients with advanced UC is particularly encouraging," said
Prof. Thomas Powles, director of the Barts Cancer Centre in London. "For the past three decades we’ve seen limited progress in therapy for bladder cancer patients, and there remains significant unmet need for new treatment options.”
Data confirm bladder cancer drug's efficacy, AstraZeneca says
Organizations in this Story
Want to get notified whenever we write about AstraZeneca Pharmaceuticals LP ?
Next time we write about AstraZeneca Pharmaceuticals LP, we'll email you a link to the story. You may edit your settings or unsubscribe at any time.Sign-up for Alerts